Recursion Pharmaceuticals (RXRX) Operating Margin (2020 - 2026)
Recursion Pharmaceuticals (RXRX) reported Operating Margin of 1985.55% for Q1 2026, down 68770.0% on a YoY basis from N/an in Q1 2025, and down 551.34% quarter-over-quarter from 304.84% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Operating Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported Operating Margin for 7 years, with the latest figure at 1985.55% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 68770.0% year-over-year to 1985.55%; the trailing twelve-month figure through Mar 2026 stood at 881.32% (up 7876.0% YoY), and the FY2025 full-year result was 867.87%, down 5377.0% from the prior year.
- Operating Margin for Q1 2026 stood at 1985.55%, down from 304.84% in the prior quarter.
- The five-year high for Operating Margin was 304.84% in Q4 2025, with the low at 4042.41% in Q4 2024.
- Historically, Operating Margin has averaged 1156.03% across 5 years, with a median of 862.54% in 2022.
- Annual changes were most pronounced in 2024 — Operating Margin sank 313405 bps — and 2025, when it soared 373757 bps.
- Recursion Pharmaceuticals' Operating Margin stood at 445.91% in 2022, then tumbled by 104 bps to 908.36% in 2023, then slumped by 345 bps to 4042.41% in 2024, then jumped by 92 bps to 304.84% in 2025, then slumped by 551 bps to 1985.55% in 2026.
- The last three Operating Margin figures came in at 1985.55% (Q1 2026), 304.84% (Q4 2025), and 3327.57% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -1,985.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,985.55% |
| Dec 31, 2025 | -304.84% |
| Sep 30, 2025 | -3,327.57% |
| Jun 30, 2025 | -916.75% |
| Mar 31, 2025 | -1,297.85% |
| Dec 31, 2024 | -4,042.41% |
| Sep 30, 2024 | -377.10% |
| Jun 30, 2024 | -697.39% |
| Mar 31, 2024 | -698.42% |
| Dec 31, 2023 | -908.36% |
| Sep 30, 2023 | -945.12% |
| Jun 30, 2023 | -741.72% |
| Mar 31, 2023 | -575.78% |
| Dec 31, 2022 | -445.91% |
| Sep 30, 2022 | -475.48% |
| Jun 30, 2022 | -862.54% |
| Mar 31, 2022 | -1,049.71% |
| Dec 31, 2021 | -2,564.55% |
| Sep 30, 2021 | -1,831.18% |
| Jun 30, 2021 | -1,605.69% |